PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2020-11-04

Date Title Company
04-Nov-2020 Molecular Diagnostics Market Size, Growth Analysis Report To 2025 Market Data Forecast
04-Nov-2020 Global Oxygen Therapy Market To Register 14.5% CAGR From 2020 to 2025 Market Data Forecast
04-Nov-2020 PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million) PerkinElmer
04-Nov-2020 South Sudan: Urgent vaccination campaign needed to stop spread of measles Médecins Sans Frontières/Doctors Without Borders (MSF)
04-Nov-2020 Calliditas closes acquisition of a controlling interest in Genkyotex SA Calliditas
04-Nov-2020 Pivotal to collaborate with Checkpoint Therapeutics on a study in patients with Cutaneous Squamous Cell Carcinoma Pivotal
04-Nov-2020 PureTech Founded Entity Gelesis Presents Three Poster Presentations at ObesityWeek® 2020 PureTech
04-Nov-2020 EPIDAREX CAPITAL PORTFOLIO COMPANY SIRAKOSS ACQUIRED BY OSSDSIGN Epidarex Capital
04-Nov-2020 Saillant Therapeutics Reports Proof of Concept of its Treatment in Heart Failure Showing Functional Reversal and Myocardial Rejuvenation Saillant Therapeutics
04-Nov-2020 myNEO launches next generation of its ImmunoEngine bioinformatic platform to identify unique neoantigens for personalised treatment of difficult-to-treat tumours myNEO
04-Nov-2020 Saillant Therapeutics Reports Proof of Concept of its Treatment in Heart Failure Showing Functional Reversal and Myocardial Rejuvenation B3C newswire
04-Nov-2020 A Cup Of Coffee Is a Healthy Way To Start The Day – Here’s Why Wired Release
04-Nov-2020 M1 Kliniken AG: Number of treatments increase by almost 20 % in Q3-2020. Comprehensive hygiene concept ensures continuation of treatment activities. M1 Kliniken AG
04-Nov-2020 Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team RELIEF THERAPEUTICS Holdings AG
04-Nov-2020 Jubilant Therapeutics to Participate in Upcoming Investor Conferences Jubilant Therapeutics Inc.
04-Nov-2020 Jubilant Therapeutics to Participate in Upcoming Investor Conferences Jubilant Therapeutics Inc.